Welcome to the e-CCO Library!

P461: Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Travis1, R. Ungaro2, A. Blake3, F. Bhayat4*, T. Card5

Created: Thursday, 21 February 2019, 9:14 AM
P461: Rapid response to appendectomy in the majority of patients with refractory Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Adamou, A.(1)*;Bercher, M.(1);Iesalnieks, I.(1);Streetz, K.(2);
Created: Friday, 14 July 2023, 11:05 AM
P461: Vedolizumab Dose Escalation in a Real-World Cohort of IBD Patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Zelinkova, Z.(1);Kadleckova, B.(1);Lucenicova, J.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn’s disease. Data from clinical practice from the eneida registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Mañosa Ciria1, A. Fernandez-Clotet2, A. Hernández-Camba3, R. Muñoz Pérez4, M. Iborra5, M. Sierra6, L. Márquez7, P. Delgado-Guillena8, D. Busquets9, M. Van Domselaar10, E. Girona11, E. Sánchez-Rodríguez12, M.D. Martín-Arranz13, R. Lorente14, D. Casas-Deza15, M. Boscá16, F. Cañete1, M. Calafat1, E. Domènech1

Created: Thursday, 30 January 2020, 10:12 AM
P462: Adalimumab improves treatment satisfaction with medication and work productivity amongst patients with ulcerative colitis in a clinical practice setting: results from INSPIRADA
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Travis*1, B. Feagan2, L. Peyrin-Biroulet3, R. Panaccione4, S. Danese5, A. Lazar6, A. Robinson7, J. Petersson7, M. Bereswill6, M. Skup7, N. Chen7, S. Wang7, R. Thakkar7, J. Chao7

Created: Friday, 22 February 2019, 9:49 AM
P462: Delayed Responders with Ustekinumab in Ulcerative Colitis Have Increased Inflammatory Burden but Similar Long-term Outcomes as Early Responders
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Wong, E.(1);Dulai, P.(2);Marshall, J.(1);Jairath, V.(3);Reinisch, W.(4);Narula, N.(1)*;
Created: Friday, 14 July 2023, 11:05 AM
P462: Dietary restrictions on inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Macedo*1, F. Portela1, A. M. Ferreira1, S. Lopes1, S. Mendes1, M. Ferreira1, L. Tomé1

Created: Friday, 22 February 2019, 9:41 AM
P462: Impact of teduglutide, a GLP-2 agonist, on inflammatory bowel disease-associated short bowel syndrome: a tertiary single-center study
Year: 2021
Source: ECCO'21 Virtual
Authors: de Seze, M.(1);Billiauws, L.(1);Bettolo, J.(1);Damas, V.(1);Hutinet, C.(1);Bonvalet, F.(2);Cazals-Hatem, D.(3);Villain, C.(1);Bouhnik, Y.(1);Joly, F.(1);Uzzan, M.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P462: Long-term outcomes of anti-TNF therapy discontinuation in patients with penetrating Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Gompertz M., Ricart E., Ordás I., Alfaro I., Lόpez A., Gallego M., Barastegui R., Giner A., Vara A., Masamunt M., Panés J.

Created: Wednesday, 20 February 2019, 10:36 AM
P462: Mucosal healing and deep remission rates with azathioprine in inflammatory bowel disease?
Year: 2018
Source: ECCO '18 Vienna
Authors:

Ü. Dağlı*, D. Özer Etik, N. Demir, S. Öcal, H. Selçuk, F. Hilmioğlu, S. Boyacıoğlu

Created: Thursday, 21 February 2019, 9:14 AM
P462: Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response
Year: 2022
Source: ECCO'22
Authors: Srinivasan, A.(1,2,3);De Cruz, P.(3,4);Sam, M.(5,6,7);Toong, C.(5,6,7,8);van Langenberg, D.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P463 Induction of endoscopic response: a network meta-analysis of induction studies comparing ontamalimab with other treatments for moderate-to-severe ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Vickers1, A. Nag2, B. Devine3, B.E. Sands4, R. Panaccione5, L. Peyrin-Biroulet6, S. Danese7, S. Vermeire8, K.J. Gorelick9, M. Goetsch10, L. Hartley1

Created: Thursday, 30 January 2020, 10:12 AM
P463: Combination therapy of fresh faecal microbial transplantation and antibiotics for ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Ishikawa*, T. Osada, K. Haga, T. Kodani, T. Shibuya, S. Watanabe

Created: Friday, 22 February 2019, 9:49 AM
P463: COVID-19 vaccination willingness and hesitancy in patients with Inflammatory Bowel Diseases (IBD): analysis of determinants in a national survey of the Italian IBD patients’ association (AMICI Onlus).
Year: 2021
Source: ECCO'21 Virtual
Authors: Costantino, A.(1);Noviello, D.(2);Conforti, F.S.(1);Aloi, M.(3);Armuzzi, A.(4);Bossa, F.(5);Ficari, F.(6);Leone, S.(7);Manguso, F.(8);Mocci, G.(9);Orlando, A.(10);Pironi, L.(11);Radice, S.(12);Rizzello, F.(13);Tongiorgi, A.(14);Costantino, C.(15);Vecchi, M.(1,2);Caprioli, F.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P463: Crohn's disease–associated anorectal cancer has a poor prognosis with high local recurrence: a subanalysis of the Nationwide Japanese Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ogino, T.(1,2)*;Mizushima, T.(2);Sekido, Y.(1);Fujii, M.(3);Eguchi, H.(1);Nezu, R.(4);Ikeuchi, H.(5);Uchino, M.(5);Futami, K.(6);Okamoto, K.(7);Ajioka, Y.(8);Sugihara, K.(9);Ishihara, S.(10);
Created: Friday, 14 July 2023, 11:05 AM
P463: Factors to determine prognosis of intestinal cancer associated with Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Shinozaki*1, R. Takahashi1

Created: Friday, 22 February 2019, 9:41 AM
P463: Long-term effects of anti-TNF therapy on bone metabolism
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. O'Morain1*, G. Farrell1, M. Hanly1, S. Veerappan1, D. McNamara1,2, N. Breslin1, C. O'Morain2, M. Healy3, B. Ryan1,2

Created: Thursday, 21 February 2019, 9:14 AM
P463: Recurrence of Crohn's disease after the first surgical intervention
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pontes García A.1, Gallardo Valverde J.M.*2, Iglesias Flores E.3, García Sanchez V.3, Díaz Lόpez C.2, Martínez Dueñas J.L.2, Medina J.2, Navarro E.2, Torres E.2, Gόmez Barbadillo J.2

Created: Wednesday, 20 February 2019, 10:36 AM
P463: Serum and mucosal Serpin E1 concentration correlates with endoscopic activity in inflammatory bowel disease - potential new activity marker
Year: 2022
Source: ECCO'22
Authors: Jójárt, B.(1);Molnár, T.(2);Kata, D.(3);Szabó, V.(1);Varga, Á.(1);Resál, T.(4);Bacsúr, P.(4);Szántó, K.(4);Földesi, I.(3);Molnár, T.(4);Maléth, J.(1);Farkas, K.(4);
Created: Friday, 11 February 2022, 3:52 PM
P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Van den Berghe1, B. Verstockt2,3, A. Gils1, M. Ferrante2,3, S. Vermeire2,3, D. Thomas1

Created: Thursday, 30 January 2020, 10:12 AM